Back to Peptipedia
MetabolismApproved · CN

Mazdutide

Mazdutide is a dual GLP-1/glucagon receptor agonist. It was approved in China in 2025 for weight management and type 2 diabetes; it does not have corresponding EU or US approval.

Approvals

CN · ApprovedCN · Approved

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

Mazdutide (IBI362) is a defined dual GLP-1/glucagon receptor agonist peptide. Its approval applies to the Chinese medicinal product.

Human research
Strong
Replication
Single research group
Clinical endpoints
Symptom- or function-related
Safety
Limited characterization
Approval
CN · ApprovedCN · Approved

The dimensions are presented separately and are not combined into an overall score.

What the source shows

A phase 3 study compared mazdutide with placebo in Chinese adults with type 2 diabetes.

Research gaps

  • ·The Chinese approval must not be presented as EU or US approval.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.